Medistep Health. (MEDISTEP)

Score breakdown: P/E: 3/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• P/E of 5.89 with 75.74% profit growth and 65.04% sales growth makes the valuation remarkably low relative to growth.
• ROCE of 37.83% indicates strong capital efficiency and a high return on employed capital.
• Piotroski F-score of 7/9 suggests solid financial fundamentals and improving health.
• Promoter holding of 68.96% aligns management interests with minority shareholders.
• Latest quarter net profit of ₹3 Cr on sales of ₹35 Cr shows meaningful profitability at a micro-cap level.

Concerns

• Book value, ROE, and debt/equity are all unavailable, limiting assessment of balance-sheet risk.
• No dividend means total return depends entirely on future growth or re-rating.
• Market cap of only ₹32 Cr implies low liquidity and potential volatility.
• Personal care is competitive, and no data proves a durable brand moat or pricing power.

AI Analysis

Medistep trades at a price of ₹19, capitalizing the entire business at just ₹32 crore. A P/E of 5.89 against profit growth of 75.74% is extraordinary; Graham taught me to be suspicious of anything that cheap. The PEG ratio of 0.08 suggests the market is either blind to the growth or the growth is not trustworthy. Latest quarter sales of ₹35 crore and net profit of ₹3 crore indicate momentum. Sales growth of 65.04% and ROCE of 37.83% are the kind of numbers I look for in a capital-efficient small business. Promoter holding at 68.96% also aligns owners with shareholders. But I cannot compute book value, ROE, or debt/equity because the data are missing. That is a red flag in a micro-cap. Buffett would say it's far better to buy a wonderful company at a fair price than a fair company at a wonderful price. Here we have a wonderful price, but I cannot yet prove the company is wonderful. Personal care is a competitive field; without brand strength, distribution edge, or pricing power, the moat is unproven. And with zero dividend, the investor depends entirely on future earnings and repricing. The Piotroski F-score of 7/9 is encouraging, but a few ratios cannot replace full accounts. At ₹19, within a 52-week range of ₹16.50–₹23.15, I would watch it but not rush. If the company delivers this growth with a clean balance sheet and expanding margins, it could be a compounding machine. Until then, it remains a promising fast grower, not a finished conviction.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer